• 中国精品科技期刊
  • 《中文核心期刊要目总览》收录期刊
  • RCCSE 中国核心期刊(5/114,A+)
  • Scopus收录期刊
  • 美国《化学文摘》(CA)收录期刊
  • WHO 西太平洋地区医学索引(WPRIM)收录期刊
  • 《中国科学引文数据库(CSCD)》核心库期刊 (C)
  • 中国科技核心期刊
  • 中国科技论文统计源期刊
  • 《日本科学技术振兴机构数据库(中国)》(JSTChina)收录期刊
  • 美国《乌利希期刊指南》(UIrichsweb)收录期刊
  • 中华预防医学会系列杂志优秀期刊(2019年)

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

无锡市Omicron毒株引起的新型冠状病毒感染者相关持续症状的特征及其影响因素

詹星雅 刘娟 冀斌 沈元

詹星雅, 刘娟, 冀斌, 沈元. 无锡市Omicron毒株引起的新型冠状病毒感染者相关持续症状的特征及其影响因素[J]. 中华疾病控制杂志, 2024, 28(2): 221-227. doi: 10.16462/j.cnki.zhjbkz.2024.02.015
引用本文: 詹星雅, 刘娟, 冀斌, 沈元. 无锡市Omicron毒株引起的新型冠状病毒感染者相关持续症状的特征及其影响因素[J]. 中华疾病控制杂志, 2024, 28(2): 221-227. doi: 10.16462/j.cnki.zhjbkz.2024.02.015
ZHAN Xingya, LIU Juan, JI Bin, SHEN Yuan. Characteristics and influencing factors of related persistent symptoms in recovered COVID-19 patients caused by Omicron variant in Wuxi City[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2024, 28(2): 221-227. doi: 10.16462/j.cnki.zhjbkz.2024.02.015
Citation: ZHAN Xingya, LIU Juan, JI Bin, SHEN Yuan. Characteristics and influencing factors of related persistent symptoms in recovered COVID-19 patients caused by Omicron variant in Wuxi City[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2024, 28(2): 221-227. doi: 10.16462/j.cnki.zhjbkz.2024.02.015

无锡市Omicron毒株引起的新型冠状病毒感染者相关持续症状的特征及其影响因素

doi: 10.16462/j.cnki.zhjbkz.2024.02.015
基金项目: 

无锡市医学发展学科 FZXK2021010

无锡市科技发展资金项目 Y20212042

详细信息
    通讯作者:

    沈元,E-mail:sarayshen@163.com

  • 中图分类号: R181.3

Characteristics and influencing factors of related persistent symptoms in recovered COVID-19 patients caused by Omicron variant in Wuxi City

Funds: 

Wuxi Medical Development Discipline Project FZXK2021010

Wuxi Science and Technology Development Fund Project Y20212042

More Information
  • 摘要:   目的  探究Omicron毒株引起的新型冠状病毒感染(新冠感染)者康复后3~4个月存在相关持续症状的特征及其影响因素,为制定随访计划、减少感染后相关持续症状提供依据。  方法  采用自编的躯体与精神神经症状量表、患者健康问卷(patient health questionnaire, PHQ-9)、压力知觉量表(Chinese perceived stress scale, CPSS)、焦虑量表(generalised anxiety disorder scale, GAD-7)和自编的疾病污名化量表进行调查。采用Mann-Whitney U检验、Kruskal-Wallis H检验、χ2检验和二元logistic回归分析模型分析。  结果  有50.7%的受访者在康复后3~4个月存在相关持续症状,共报告躯体与精神神经症状47种,疲劳乏力是最常见的躯体症状(50.5%),失眠是最常见的精神神经症状(24.3%),抑郁和焦虑均与躯体或精神神经症状伴随出现。女性(β=0.70,OR=2.01,95% CI: 1.04~3.86,P=0.037)、隔离期间存在临床症状(β=0.78,OR=2.17,95% CI: 1.13~4.20,P=0.021)、中高压力(β=1.68,OR=5.35,95% CI: 2.14~13.38,P<0.001)、严重污名化(β=1.03,OR=2.79,95% CI: 1.33~5.83,P=0.006)是新冠感染者出院3~4个月后存在持续症状的危险因素。  结论  部分新冠感染者康复后3~4个月时仍存在相关持续症状。重点关注可能出现相关持续症状的高风险人群,并同时在医疗保健和精神心理卫生方面给予支持。
  • 图  1  躯体与精神神经症状共现网络

    括号中数据为症状总响应人次与总响应人数占比。

    Figure  1.  Somatic and psychoneurotic symptom co-occurrence network

    Data in parentheses are percentages of total symptom responders and total responders.

    表  1  不同基本特征新型冠状病毒感染者存在相关持续症状情况的比较

    Table  1.   Current status and difference analysis of persistent symptoms of COVID-19 in patients with different basic characteristics

    变量  Variable 无持续症状受访者人数(占比/%)
    Number of no persistent symptoms(proportion/%)
    有持续症状受访者人数(占比/%)
    Number of having persistent symptoms(proportion/%)
    χ2
    value
    P
    value
    性别  Gender 1.775 0.183
        男性  Male 52(52.5) 44(43.1)
        女性  Female 47(47.5) 58(56.9)
    年龄组/岁  Age group/years 0.785 0.940
        18~<31 15(15.2) 19(18.6)
        31~<41 21(21.2) 23(22.5)
        41~<51 28(28.3) 29(28.4)
        51~<61 29(29.3) 26(25.5)
        ≥61 6(6.1) 5(4.9)
    原籍  Domicile place 3.445 0.179
        无锡市  Wuxi City 28(28.3) 19(18.6)
        江苏省其他市  Other cities in Jiangsu Province 29(29.3) 40(39.2)
        省外  Other Provinces 42(42.4) 43(42.2)
    职业  Occupation 4.406 0.493
        工人  Workers 46(46.5) 39(38.2)
        技术人员  Technicists 16(16.2) 24(23.5)
        家务、待业或离退人员  Housework, unemployment or retiree 12(12.1) 18(17.6)
        个体户  Individual household 7(7.1) 5(4.9)
        商业服务  Commercial service 8(8.1) 5(4.9)
        其他  Others 10(10.1) 11(10.8)
    疫苗接种剂次  Dose of vaccine 2.890 0.409
        未接种  Unvaccinated 4(4.0) 3(2.9)
        1剂次  dose 2(2.0) 2(2.0)
        2剂次  doses 21(21.2) 13(12.7)
        3剂次  doses 72(72.7) 84(82.4)
    隔离期间存在临床症状  Presentation of clinical symptoms during the quarantine 9.112 0.011
        否  No 65(65.7) 46(45.1)
        是  Yes 30(30.3) 52(51.0)
        未知  Unknown 4(4.0) 4(3.9)
    基础疾病  Comorbidity 3.418 0.181
        无  No 51(51.5) 54(52.9)
        有 Yes 9(9.1) 17(16.7)
        未知  Unknown 39(39.4) 31(30.4)
    下载: 导出CSV

    表  2  不同特征受访者的症状群得分差异

    Table  2.   Differences in symptom cluster scores among respondents with different characteristics

    变量  Variable 躯体与精神神经症状总分
    Total score of physical and neuropsychological symptoms
    PHQ-9总分
    Total score of PHQ-9
    GAD-7总分
    Total score of GAD-7
    性别 Gender
        男性  Male 0.00(0.00, 8.00) 0.00(0.00, 2.00) 0.00(0.00, 1.00)
        女性  Female 1.00(0.00, 10.50) 0.00(0.00, 2.00) 0.00(0.00, 1.00)
        Z值  value -0.960 -0.472 -0.728
        P值  value 0.337 0.637 0.467
    年龄组/岁  Age group/years
        18~ < 31 3.00(0.00, 5.25) 0.00(0.00, 2.00) 0.00(0.00, 0.00)
        31~ < 41 2.00(0.00, 12.75) 1.00(0.00, 3.00) 0.00(0.00, 1.00)
        41~ < 51 1.00(0.00, 14.50) 0.00(0.00, 2.25) 0.00(0.00, 1.00)
        51~ < 61 0.00(0.00, 7.00) 0.00(0.00, 2.00) 0.00(0.00, 1.00)
        ≥61 0.00(0.00, 6.00) 0.00(0.00, 0.00) 0.00(0.00, 1.00)
        H值  value 1.426 6.343 7.733
        P值  value 0.840 0.175 0.102
    原籍  Domicile place
        无锡市  Wuxi City 0.00(0.00, 8.00) 0.00(0.00, 2.00) 0.00(0.00, 1.00)
        江苏省其他市  Other cities in Jiangsu Province 2.00(0.00, 13.50) 0.00(0.00, 3.00) 0.00(0.00, 1.00)
        省外  Other Provinces 1.00(0.00, 5.50) 1.00(0.00, 2.00) 0.00(0.00, 1.00)
        H值  value 3.909 2.708 1.368
        P值  value 0.142 0.258 0.505
    职业  Occupation
        工人  Workers 0.00(0.00, 7.00) 0.00(0.00, 1.00) 0.00(0.00, 0.00)
        技术人员  Technicists 4.50(0.00, 13.50) 1.00(0.00, 3.75) 0.00(0.00, 1.75)
        家务、待业或离退人员  Housework, unemployment or retiree 5.00(0.00, 17.25) 1.00(0.00, 4.00) 0.00(0.00, 1.25)
        个体户  Individual household 0.00(0.00, 4.75) 1.00(0.00, 2.00) 0.00(0.00, 1.50)
        商业服务  Commercial service 0.00(0.00, 9.50) 0.00(0.00, 2.00) 0.00(0.00, 0.50)
        其他  Others 1.00(0.00, 4.00) 0.00(0.00, 2.00) 0.00(0.00, 1.00)
        H值  value 7.516 10.833 8.981
        P值  value 0.185 0.055 0.110
    疫苗接种剂次  Dose of vaccine
        未接种  Unvaccinated 0.00(0.00, 11.00) 1.00(0.00, 4.00) 2.00(0.00, 2.00)
        1剂次  dose 4.00(0.00, 8.00) 1.00(0.25, 4.00)
        2剂次  doses 0.00(0.00, 5.00) 0.00(0.00, 2.00) 0.00(0.00, 0.00)
        3剂次 doses 1.50(0.00, 10.00) 0.00(0.00, 2.00) 0.00(0.00, 1.00)
        H值  value 2.098 1.811 9.713
        P值  value 0.552 0.612 0.021
    隔离期间存在临床症状 Presentation of clinical symptoms during the quarantine
        否  No 0.00(0.00, 6.00) 0.00(0.00, 1.00) 0.00(0.00, 1.00)
        是 Yes 4.00(0.00, 11.00) 1.00(0.00, 3.00) 0.00(0.00, 1.00)
        未知 Unknown 1.50(0.00, 4.50) 0.00(0.00, 1.00)
        H值  value 6.454 8.255 4.186
        P值  value 0.040 0.016 0.123
    基础疾病  Comorbidity
        无  No 1.00(0.00, 10.50) 0.00(0.00, 2.00) 0.00(0.00, 1.00)
        有 Yes 5.00(0.00, 22.25) 1.00(0.00, 4.25) 1.00(0.00, 2.00)
        未知  Unknown 0.00(0.00, 6.25) 0.00(0.00, 1.00) 0.00(0.00, 0.00)
        H值  value 5.619 11.275 9.423
        P值  value 0.060 0.004 0.009
    知觉压力水平  Level of perceived Stress
        低  Low 0.00(0.00, 5.00) 0.00(0.00, 1.00) 0.00(0.00, 0.00)
        中  Moderate 10.50(3.00, 17.75) 3.00(1.25, 4.00) 1.00(1.00, 2.00)
        高  High
        H值  value 32.856 62.347 66.731
        P值  value <0.001 <0.001 <0.001
    污名化水平  Level of stigmatization
        轻度  Low 0.00(0.00, 2.00) 0.00(0.00, 0.00) 0.00(0.00, 0.00)
        中度  Moderate 0.00(0.00, 5.00) 0.00(0.00, 1.50) 0.00(0.00, 0.00)
        严重  Severe 8.50(0.00, 17.25) 2.00(1.00, 4.25) 1.00(0.00, 2.00)
        H值  value 36.711 59.152 59.419
        P值  value <0.001 <0.001 <0.001
    注:PHQ-9, 患者健康问卷; GAD-7, 焦虑量表;“―”表示此类人群样本量不足,用中位数和四分位数无法表示。
    ①以M(P25P75)表示。
    Note: PHQ-9, patient health questionnaire; GAD-7, generalised anxiety disorder scale; The "―" symbol indicates that the sample size of this population is insufficient to be represented by the median and quartile.
    M(P25P75).
    下载: 导出CSV

    表  3  新型冠状病毒感染相关持续症状多因素分析

    Table  3.   Multivariate analysis of persistent symptoms associated with COVID-19

    变量  Variable β
    value
    sx Wald
    value
    OR值value
    (95% CI)
    P
    value
    性别 Gender
        男性  Male 1.00
        女性  Female 0.70 0.33 4.33 2.01(1.04~3.86) 0.037
    年龄/岁 Age/years -0.02 0.02 1.25 0.98(0.96~1.01) 0.264
    基础疾病 Comorbidity
        无  No 1.00
        有 Yes 0.53 0.58 0.86 1.71(0.55~5.28) 0.355
        未知  Unknown 0.42 0.38 1.24 1.52(0.73~3.17) 0.266
    隔离期间存在临床症状  Presentation of clinical symptoms during the quarantine
        否  No 1.00
        是  Yes 0.78 0.34 5.34 2.17(1.13~4.20) 0.021
        未知  Unknown 0.30 0.80 0.14 1.35(0.28~6.48) 0.705
    知觉压力水平  Level of perceived stress
        低 Low 1.00
        中高 Moderate or high 1.68 0.47 12.87 5.35(2.14~13.38) <0.001
    污名化水平  Level of stigmatization
        轻中度  Low or moderate 1.00
        严重  Severe 1.03 0.38 7.43 2.79(1.33~5.83) 0.006
    下载: 导出CSV
  • [1] Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis [J]. medRxiv, 2021: 2021.01.27.21250617. DOI: 10.1101/2021.01.27.21250617.
    [2] World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus. [EB/OL]. (2021-10-06) [2022-06-01]. https://iris.who.int/handle/10665/345824.
    [3] 中华人民共和国国家卫生健康委员会. 关于印发新型冠状病毒肺炎诊疗方案(试行第九版)的通知[EB/OL]. (2022-03-15) [2022-06-01]. http://www.nhc.gov.cn/yzygj/s7653p/202203/b74ade1ba4494583805a3d2e40093d88.shtml.
    [4] Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review [J]. JAMA Netw Open, 2021, 4(5): e2111417. DOI: 10.1001/jamanetworkopen.2021.11417.
    [5] Wahlgren C, Forsberg G, Divanoglou A, et al. Two-year follow-up of patients with post-COVID-19 condition in Sweden: a prospective cohort study [J]. Lancet Reg Health Eur, 2023, 28: 100595. DOI: 10.1016/j.lanepe.2023.100595.
    [6] Antonelli M, Pujol JC, Spector TD, et al. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2 [J]. Lancet, 2022, 399(10343): 2263-2264. DOI: 10.1016/S0140-6736(22)00941-2.
    [7] Huang CL, Huang LX, Wang YM, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study [J]. Lancet, 2023, 401(10393): e21-e33. DOI: 10.1016/S0140-6736(23)00810-3.
    [8] Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome [J]. Nat Med, 2021, 27(4): 601-615. DOI: 10.1038/s41591-021-01283-z.
    [9] Scully EP, Haverfield J, Ursin RL, et al. Considering how biological sex impacts immune responses and COVID-19 outcomes [J]. Nat Rev Immunol, 2020, 20(7): 442-447. DOI: 10.1038/s41577-020-0348-8.
    [10] Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19 [J]. J Infect, 2020, 81(6): e4-e6. DOI: 10.1016/j.jinf.2020.08.029.
    [11] Taquet M, Geddes JR, Husain M, et al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records [J]. Lancet Psychiatry, 2021, 8(5): 416-427. DOI: 10.1016/S2215-0366(21)00084-5.
    [12] Ettman CK, Abdalla SM, Cohen GH, et al. Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic [J]. JAMA Netw Open, 2020, 3(9): e2019686. DOI: 10.1001/jamanetworkopen.2020.19686.
    [13] Uvais NA, Aziz F, Hafeeq B. COVID-19-related stigma and perceived stress among dialysis staff [J]. J Nephrol, 2020, 33(6): 1121-1122. DOI: 10.1007/s40620-020-00833-x.
    [14] Bagcchi S. Stigma during the COVID-19 pandemic [J]. Lancet Infect Dis, 2020, 20(7): 782. DOI: 10.1016/S1473-3099(20)30498-9.
  • 加载中
图(1) / 表(3)
计量
  • 文章访问数:  36
  • HTML全文浏览量:  9
  • PDF下载量:  1
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-12-01
  • 修回日期:  2024-01-24
  • 网络出版日期:  2024-03-30
  • 刊出日期:  2024-02-10

目录

    /

    返回文章
    返回